Stephanie Stojanovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephanie Stojanovic has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Eve Denton
Allergy, Asthma and Clinical Immunology, The Alfred Hospital, Melbourne 3004, VIC Australia; School of Public Health & Preventive Medicine, Monash University, Melbourne 3004, VIC, Australia
4 shared publicationsJanine Mahoney
Speech Pathology, The Alfred Hospital, Melbourne 3004, VIC Australia
4 shared publicationsMark Hew
Allergy, Asthma and Clinical Immunology, The Alfred Hospital, Melbourne 3004, VIC Australia; School of Public Health & Preventive Medicine, Monash University, Melbourne 3004, VIC, Australia
4 shared publicationsAsger Sverrild
Allergy, Asthma and Clinical Immunology, The Alfred Hospital, Melbourne 3004, VIC Australia; Dept of Respiratory Medicine, University Hospital Bispebjerg, Copenhagen, Denmark
3 shared publicationsKavitha Garuna Murthee
Department of Internal Medicine, Singapore General Hospital, Singapore
3 shared publications- Robyn Elizabeth O'HEhir
Alfred Hospital
3 shared publications
Latest Publications
- Open Access
Third dose COVID-19 vaccination elicits immune memory in patients with inborn errors of immunity even in absence of neutralizing antibodies
Background: Immunocompromised people, including those with Inborn Errors of Immunity (IEI), are at increased risk of severe disease from viral infections. Therefore, regular booster vaccinations are recommended for SARS-CoV-2 and influenza, but it is unclear if these elicit protective immunity. Objective: Comprehensive evaluation of adaptive immune responses, including SARS-COV-2 specific antibodies, memory B-(Bmem) and memory T-cells (Tmem), to COVID-19 vaccination in IEI patients. Methods: Blood samples were collected at 1-month post doses 2 and 3 of the ancestral COVID-19 vaccine, SARS-CoV-2 neutralizing antibodies (NAb) and Spike receptor binding domain (RBD) specific IgG were determined in 25 IEI patients and 29 controls. Ancestral Spike specific Tmem, and ancestral and Omicron subvariant RBD-specific Bmem were evaluated with flow cytometry. Results: After dose 2, IEI patients had significantly lower Nab, RBD-specific IgG and Bmem against ancestral and Omicron subvariants. Third dose vaccination boosted NAb, IgG and Bmem levels, but these remained lower than healthy controls. Especially IgG1 + Bmem were lower in the IEI patients, while they carried higher frequencies of CD71 + ancestral RBD-specific Bmem. IEI patients and controls had similar numbers of Spike-specific CD4 + and CD8 + Tmem after both doses. However, patients’ Tmem had lower CD69 expression and reduced cytokine co-expression. While 9/25 IEI patients did not have NAb after dose 3, all had detectable SARS-CoV-2 specific IgG, Bmem- and/or Tmem. Conclusion: Patients with IEI form lower levels of antibodies and immune memory cells to COVID-19 vaccination than controls. Still, all patients displayed formation of adaptive immune memory. This suggests a beneficial effect of vaccination, and supports the strategy for offering regular booster vaccinations to limit severe COVID-19 in this at-risk population. KEY MESSAGES: Whilst antibody-deficient patients fail to generate NAb, all evaluated IEI patients could form spike-specific Tmem after COVID-19 vaccination. A 3-dose regimen boosted humoral and/or cellular responses in 60% of IEI patients, reinforcing the importance of prioritizing this population for early and repeated vaccination. Comprehensive analysis of Bmem and Tmem responses revealed COVID-19 vaccination elicited adaptive immunity, underscoring the need for monitoring of immune cells in addition to serology in immunodeficient populations. CAPSULE SUMMARY: Following 3-dose COVID-19 vaccination, all adult patients with inborn errors of immunity formed memory B- and/or memory T cells regardless of whether neutralizing antibodies are elicited. Therefore, IEI patients generate adaptive immunity to COVID-19 vaccination.
Open AccessThird dose COVID-19 vaccination elicits immune memory in patients with inborn errors of immunity even in absence of neutralizing antibodies
Background: Immunocompromised people, including those with Inborn Errors of Immunity (IEI), are at increased risk of severe disease from viral infections. Therefore, regular booster vaccinations are recommended for SARS-CoV-2 and influenza, but it is unclear if these elicit protective immunity. Objective: Comprehensive evaluation of adaptive immune responses, including SARS-COV-2 specific antibodies, memory B-(Bmem) and memory T-cells (Tmem), to COVID-19 vaccination in IEI patients. Methods: Blood samples were collected at 1-month post doses 2 and 3 of the ancestral COVID-19 vaccine, SARS-CoV-2 neutralizing antibodies (NAb) and Spike receptor binding domain (RBD) specific IgG were determined in 25 IEI patients and 29 controls. Ancestral Spike specific Tmem, and ancestral and Omicron subvariant RBD-specific Bmem were evaluated with flow cytometry. Results: After dose 2, IEI patients had significantly lower Nab, RBD-specific IgG and Bmem against ancestral and Omicron subvariants. Third dose vaccination boosted NAb, IgG and Bmem levels, but these remained lower than healthy controls. Especially IgG1 + Bmem were lower in the IEI patients, while they carried higher frequencies of CD71 + ancestral RBD-specific Bmem. IEI patients and controls had similar numbers of Spike-specific CD4 + and CD8 + Tmem after both doses. However, patients’ Tmem had lower CD69 expression and reduced cytokine co-expression. While 9/25 IEI patients did not have NAb after dose 3, all had detectable SARS-CoV-2 specific IgG, Bmem- and/or Tmem. Conclusion: Patients with IEI form lower levels of antibodies and immune memory cells to COVID-19 vaccination than controls. Still, all patients displayed formation of adaptive immune memory. This suggests a beneficial effect of vaccination, and supports the strategy for offering regular booster vaccinations to limit severe COVID-19 in this at-risk population. KEY MESSAGES: Whilst antibody-deficient patients fail to generate NAb, all evaluated IEI patients could form spike-specific Tmem after COVID-19 vaccination. A 3-dose regimen boosted humoral and/or cellular responses in 60% of IEI patients, reinforcing the importance of prioritizing this population for early and repeated vaccination. Comprehensive analysis of Bmem and Tmem responses revealed COVID-19 vaccination elicited adaptive immunity, underscoring the need for monitoring of immune cells in addition to serology in immunodeficient populations. CAPSULE SUMMARY: Following 3-dose COVID-19 vaccination, all adult patients with inborn errors of immunity formed memory B- and/or memory T cells regardless of whether neutralizing antibodies are elicited. Therefore, IEI patients generate adaptive immunity to COVID-19 vaccination.
- 8 February 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 134 (5) , 563-569
Mannitol provocation enhances laryngoscopic diagnosis of suspected inducible laryngeal obstruction
- 8 February 2025
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 134 (5) , 563-569
Mannitol provocation enhances laryngoscopic diagnosis of suspected inducible laryngeal obstruction
- Open Access
Trait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment
Background: Multidisciplinary systematic assessment improves outcomes in difficult‐to‐treat asthma, but without clear response predictors. Using a treatable‐traits framework, we stratified patients by trait profile, examining clinical impact and treatment responsiveness to systematic assessment.Methods: We performed latent class analysis using 12 traits on difficult‐to‐treat asthma patients undergoing systematic assessment at our institution. We examined Asthma Control Questionnaire (ACQ‐6) and Asthma Quality of Life Questionnaire (AQLQ) scores, FEV1, exacerbation frequency, and maintenance oral corticosteroid (mOCS) dose, at baseline and following systematic assessment.Results: Among 241 patients, two airway‐centric profiles were characterized by early‐onset with allergic rhinitis (n = 46) and adult onset with eosinophilia/chronic rhinosinusitis (n = 60), respectively, with minimal comorbid or psychosocial traits; three non‐airway‐centric profiles exhibited either comorbid (obesity, vocal cord dysfunction, dysfunctional breathing) dominance (n = 51), psychosocial (anxiety, depression, smoking, unemployment) dominance (n = 72), or multi‐domain impairment (n = 12). Compared to airway‐centric profiles, non‐airway‐centric profiles had worse baseline ACQ‐6 (2.7 vs. 2.2, p < .001) and AQLQ (3.8 vs. 4.5, p < .001) scores. Following systematic assessment, the cohort showed overall improvements across all outcomes. However, airway‐centric profiles had more FEV1 improvement (5.6% vs. 2.2% predicted, p < .05) while non‐airway‐centric profiles trended to greater exacerbation reduction (1.7 vs. 1.0, p = .07); mOCS dose reduction was similar (3.1 mg vs. 3.5 mg, p = .782).Conclusion: Distinct trait profiles in difficult‐to‐treat asthma are associated with different clinical outcomes and treatment responsiveness to systematic assessment. These findings yield clinical and mechanistic insights into difficult‐to‐treat asthma, offer a conceptual framework to address disease heterogeneity, and highlight areas responsive to targeted intervention.
Open AccessTrait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment
Background: Multidisciplinary systematic assessment improves outcomes in difficult‐to‐treat asthma, but without clear response predictors. Using a treatable‐traits framework, we stratified patients by trait profile, examining clinical impact and treatment responsiveness to systematic assessment.Methods: We performed latent class analysis using 12 traits on difficult‐to‐treat asthma patients undergoing systematic assessment at our institution. We examined Asthma Control Questionnaire (ACQ‐6) and Asthma Quality of Life Questionnaire (AQLQ) scores, FEV1, exacerbation frequency, and maintenance oral corticosteroid (mOCS) dose, at baseline and following systematic assessment.Results: Among 241 patients, two airway‐centric profiles were characterized by early‐onset with allergic rhinitis (n = 46) and adult onset with eosinophilia/chronic rhinosinusitis (n = 60), respectively, with minimal comorbid or psychosocial traits; three non‐airway‐centric profiles exhibited either comorbid (obesity, vocal cord dysfunction, dysfunctional breathing) dominance (n = 51), psychosocial (anxiety, depression, smoking, unemployment) dominance (n = 72), or multi‐domain impairment (n = 12). Compared to airway‐centric profiles, non‐airway‐centric profiles had worse baseline ACQ‐6 (2.7 vs. 2.2, p < .001) and AQLQ (3.8 vs. 4.5, p < .001) scores. Following systematic assessment, the cohort showed overall improvements across all outcomes. However, airway‐centric profiles had more FEV1 improvement (5.6% vs. 2.2% predicted, p < .05) while non‐airway‐centric profiles trended to greater exacerbation reduction (1.7 vs. 1.0, p = .07); mOCS dose reduction was similar (3.1 mg vs. 3.5 mg, p = .782).Conclusion: Distinct trait profiles in difficult‐to‐treat asthma are associated with different clinical outcomes and treatment responsiveness to systematic assessment. These findings yield clinical and mechanistic insights into difficult‐to‐treat asthma, offer a conceptual framework to address disease heterogeneity, and highlight areas responsive to targeted intervention.
- 10 July 2022
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 129 (4) , 517-519
Transient acquired donor peanut allergy presenting as life-threatening anaphylaxis following lung transplantation
- 10 July 2022
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 129 (4) , 517-519
Transient acquired donor peanut allergy presenting as life-threatening anaphylaxis following lung transplantation
- 10 May 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (8) , 924-928
Laryngoscopy diagnosis of inducible laryngeal obstruction during supervised challenge for suspected anaphylaxis
- 10 May 2022
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (8) , 924-928
Laryngoscopy diagnosis of inducible laryngeal obstruction during supervised challenge for suspected anaphylaxis
- 1 February 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (2) , 602-608.e1
Diagnostic and Therapeutic Outcomes Following Systematic Assessment of Patients with Concurrent Suspected Vocal Cord Dysfunction and Asthma
- 1 February 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (2) , 602-608.e1
Diagnostic and Therapeutic Outcomes Following Systematic Assessment of Patients with Concurrent Suspected Vocal Cord Dysfunction and Asthma
- 22 December 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (12) , 2133-2139
Repeated adrenaline requirements for anaphylaxis
We examined the pattern of adrenaline administration in patients presenting with anaphylaxis. Forty-four percent required repeated adrenaline administration, among whom there had been greater cardiorespiratory compromise. Repeated administration was more frequent in males and older patients, and those triggered by insect sting or unknown cause; no other patient factors were identified. This study supports the provision of two adrenaline auto-injectors to all anaphylaxis patients.
- 22 December 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 51 (12) , 2133-2139
Repeated adrenaline requirements for anaphylaxis
We examined the pattern of adrenaline administration in patients presenting with anaphylaxis. Forty-four percent required repeated adrenaline administration, among whom there had been greater cardiorespiratory compromise. Repeated administration was more frequent in males and older patients, and those triggered by insect sting or unknown cause; no other patient factors were identified. This study supports the provision of two adrenaline auto-injectors to all anaphylaxis patients.
- 1 April 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (4) , 1660-1666
Safety of Intravenous Iron Following Infusion Reactions
- 1 April 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (4) , 1660-1666
Safety of Intravenous Iron Following Infusion Reactions
- Open Access
- 18 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (54)
Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
Memory B cells specific for SARS-CoV-2 spike and nucleocapsid proteins persist in peripheral blood after recovery from COVID-19.
- 18 December 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (54)
Open AccessRapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence
Memory B cells specific for SARS-CoV-2 spike and nucleocapsid proteins persist in peripheral blood after recovery from COVID-19.